Cargando…
Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?
BACKGROUND: SelectMDx is a urinary biomarker test for determining prostate cancer risk. AIM: In a group of patients with a biopsy proven prostate cancer (PCa) who had undergone a multi parametric Magnetic Resonance Imaging (mpMRI) and urinary biomarker test with SelectMDx, we studied the additive va...
Autores principales: | Rahnama'i, Mohammad Sajjad, Bach, Christian, Schulze‐Hagen, Maximilian, Kuhl, Christiane K, Vögeli, Thomas Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714534/ https://www.ncbi.nlm.nih.gov/pubmed/33931984 http://dx.doi.org/10.1002/cnr2.1396 |
Ejemplares similares
-
SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study
por: Maggi, Martina, et al.
Publicado: (2021) -
Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer
por: Visser, Wieke C. H., et al.
Publicado: (2022) -
A SelectMDx/magnetic resonance imaging‐based nomogram to diagnose prostate cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2022) -
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men
por: Hendriks, Rianne J., et al.
Publicado: (2021) -
The Scientific Value of Abstracts on Prostate Cancer Presented at the European Association of Urology Congresses
por: Ataei, Jasmin, et al.
Publicado: (2021)